Peppermint Oil Industry Global Key Vendors,Manufacturers,Suppliers and Analysis Market Report 2024

PUNE, INDIA, November 29, 2019 / —

WiseGuyReports.Com Publish a New Market Research Report On –“ Peppermint Oil Industry Global Key Vendors,Manufacturers,Suppliers and Analysis Market Report 2024”.

Peppermint Oil Market 2019

Description: –

The global peppermint oil market is expected to grow at a good rate in the near future. The study analyses the market and predicting the growth in the market based on past trends, motivating and restraining factors influencing the market in various different regions of the world and helps you make better business decisions. Peppermint is an herb which is a natural cross between two different types of mint that is, water mint and spearmint and grows throughout Europe and North America. Peppermint is a prevalent flavouring agent in foods, and its oil is used to create fragrance in cleansers like soaps and cosmetics. Peppermint oil is also used as a dietary supplement for irritable bowel syndrome (IBS), the common cold, other digestive problems, headaches and other conditions.

Get a Sample Report @

For more information or any query mail at

Listed key Players

Agson Global
Arora Aromatics
Swati Menthol & Allied Chem
Silverline Chemicals
Mentha & Allied Products
Hindustan Mint&Agro Products
A.G. Industries
AOS Products
Aromatic & Allied Chemicals
Jindal Drugs
Paras Perfumers
KM Chemicals
Neeru Enterprises
WILD Flavors
Essex Laboratories
Dongtai Venus spice
Anhui Fenghua spice
Jiangxi cedar natural medicinal oil
Natural plant oil from Ji'an sea

The increase in demand for aromatherapy treatments is estimated to boost the growth of the market. The rising customer awareness related to the use of safe, natural and organic products is also expected to drive the elevation of the market. Growing disposable income and awareness of personal care has given rise to the demand for oral care and confectionery products in the rural areas, which is the main motivator for the growth of the global peppermint oil market. The latest outbreak of Zika virus and ailments such as dengue and malaria has elevated the demand for natural mosquito repellents and the utilization of peppermint oil in these repellent which is also estimated to cause a rise in the market. However, the increase in cost and decline in the manufacturing of peppermint oil is anticipated to hinder the growth of global peppermint oil market in the coming years.

Market Segmentation:

The peppermint oil market is segmented by applications and region. The peppermint oil market is segmented by applications as oral products, confectionary products, pharmaceutical products, tobacco products and fragrance products. The oral products are further segmented into toothpaste, oral spray and mouthwash. The confectionary products are also fragmented further into chewing gum, cough and throat lozenges and candies. The pharmaceutical products are further segmented into rubbing alcohol, analgesic balms, medicated oils and drugs. The tobacco products are segmented as cigarettes and chewing tobacco. Furthermore, fragrance products are also sub-classified into aftershave lotions, shampoo, soap and bathing oil.

Regional Analysis:

Regionally, the global peppermint oil market is segmented as North America, Europe, Southeast Asia, China, Japan and India. Currently, regions of North America and Europe are the leading market players in the peppermint oil market owing to increased disposable income, rising demand for aromatherapy treatments and rise in demand for organic products. However, the trend is about to change in the future with Asia Pacific emerging as a key region for the market. The positive factors attributed to the rise of Asian markets is its large population size, improved economic conditions and increase in the awareness for organic products.

Enquiry About Report @

Table of Contents – Major key Points

Section 1 Peppermint Oil Product Definition
Section 2 Global Peppermint Oil Market Manufacturer Share and Market Overview
Section 3 Manufacturer Peppermint Oil Business Introduction
Section 4 Global Peppermint Oil Market Segmentation (Region Level)
Section 5 Global Peppermint Oil Market Segmentation (Product Type Level)
Section 6 Global Peppermint Oil Market Segmentation (Industry Level)
Section 7 Global Peppermint Oil Market Segmentation (Channel Level)
Section 8 Peppermint Oil Market Forecast 2019-2024


About US:
Wise Guy Reports is part of the Wise Guy Consultants Pvt. Ltd. and offers premium progressive statistical surveying, market research reports, analysis & forecast data for industries and governments around the globe.

email us here

Source: EIN Presswire

Over The Counter and OTC Test Market 2019, Global Industry Analysis, Size, Share, Growth, Trends and Forecast – 2024

A New Market Study, titled “Over The Counter and OTC Test Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

PUNE, MARKETERSMEDIA, INDIA, November 29, 2019 / — Summary

A New Market Study, titled “Over The Counter and OTC Test Market Upcoming Trends, Growth Drivers and Challenges” has been featured on WiseGuyReports.

This report provides in depth study of “Over The Counter and OTC Test Market” using SWOT analysis i.e. Strength, Weakness, Opportunities and Threat to the organization. The Over The Counter and OTC Test Market report also provides an in-depth survey of key players in the market which is based on the various objectives of an organization such as profiling, the product outline, the quantity of production, required raw material, and the financial health of the organization.

This market report offers a comprehensive analysis of the global Over The Counter and OTC Test market. This report focused on Over The Counter and OTC Test market past and present growth globally. Global research on Global Over The Counter and OTC Test Industry presents a market overview, product details, classification, market concentration, and maturity study. The market value and growth rate from 2019-2025 along with industry size estimates are explained.

The latest advancements in Over The Counter and OTC Test industry and changing market dynamics are key driving factors to depict tremendous growth. Also, the risk factors which will have a significant impact on the Global Over The Counter and OTC Test industry in the coming years are listed in this report. The revenue-generating Over The Counter and OTC Test types, applications, and key regions are evaluated. Top growing regions and Over The Counter and OTC Test industry presence cover Asia-Pacific, North America, Europe, Middle East, African countries and South America. This Over The Counter and OTC Test business study also analyzes the top countries in these regions with their market potential.

This report focuses on the global Over The Counter and OTC Test status, future forecast, growth opportunity, key market and key players. The study objectives are to present the Over The Counter and OTC Test development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.

The key players covered in this study
Siemens Healthcare
Johnson & Johnson
Bio-Rad Laboratories
Nova Biomedical
Trividia Health
Trinity Biotech
OraSure Technologies
i-Health Lab
LIA Diagnostics
Biolytical Laboratories

Request a Free Sample Report @

Market segment by Type, the product can be split into
Glucose Monitoring Test
Cholesterol Monitoring Test
Infectious Disease Testing
Fecal Occult Test
Urine Analysis Test
Drug Abuse Test

Market segment by Application, split into
Workplace Testing
Criminal Justice Testing
Disease Testing

Market segment by Regions/Countries, this report covers
North America
Southeast Asia
Central & South America

The study objectives of this report are:
To analyze global Over The Counter and OTC Test status, future forecast, growth opportunity, key market and key players.
To present the Over The Counter and OTC Test development in North America, Europe, China, Japan, Southeast Asia, India and Central & South America.
To strategically profile the key players and comprehensively analyze their development plan and strategies.
To define, describe and forecast the market by product type, market and key regions.

In this study, the years considered to estimate the market size of Over The Counter and OTC Test are as follows:
History Year: 2014-2018
Base Year: 2018
Estimated Year: 2019
Forecast Year 2019 to 2025
For the data information by region, company, type and application, 2018 is considered as the base year. Whenever data information was unavailable for the base year, the prior year has been considered.

Major Key Points in Table of Content
1 Report Overview
2 Global Growth Trends
3 Market Share by Key Players
4 Breakdown Data by Type and Application
5 North America
6 Europe
7 China
8 Japan
9 Southeast Asia
10 India
11 Central & South America
12 International Players Profiles
13 Market Forecast 2019-2025
14 Analyst’s Viewpoints/Conclusions
15 Appendix


At Any Query @

Report Summary:
In the first section, the Global Over The Counter and OTC Test Market report presents industry overview, definition, and scope. The second part briefs about the Global Over The Counter and OTC Test industry bifurcation by Type, Application and Geographical regions. The top industry players, revenue analysis, and sales margin are explained. The production and consumption scenario is specified.

The SWOT analysis by players, the growth rate for each type, application, and the region is covered. A 5-year forecast Global Over The Counter and OTC Test industry perspective will lead to profitable business plans and informed moves. Towards, the end data sources, research methodology, and findings are offered.

Contact Us:

Ph: +1-646-845-9349 (US); Ph: +44 208 133 9349 (UK)

email us here

Source: EIN Presswire

Registration Opens for SMi’s 3rd Annual Pharmaceutical Microbiology East Coast Conference

Pharmaceutical Microbiology East Coast Conference

Pharmaceutical Microbiology East Coast Conference

The agenda and speaker line-up for the upcoming Pharmaceutical Microbiology East Coast Conference, which will convene in Boston in April 2020, has been released

BOSTON, USA, November 28, 2019 / — The pharmaceutical microbiology industry has seen many changes during the progression into the 21st century. With advances in rapid microbiological methods, constant regulatory updates, enhanced knowledge of innovation therapeutics, and novel testing methods, this industry is ever expanding.

Registration for the upcoming Pharmaceutical Microbiology East Coast Conference, which will convene in Boston, USA on the 29th and 30th of April 2020, is now open. Delegates can join industry experts to discuss and analyse the latest advances and challenges within the industry, explore data integrity considerations for conventional and rapid microbiology methods, analyse arising issues with environmental monitoring and gain insight into an industry perspective on automated endotoxin testing and process automation.

For those interested in attending, there is an early bird offer with a $400 saving for bookings made by 13th December 2019. Visit

• Discuss end-to-end contamination risk assessment autologous cell therapy from Juno Therapeutics
• Gain valuable insight towards microbiological quality considerations in non-sterile manufacturing and control of BCC from Parexel
• Examine the microbial control strategies for pharmaceutical compounding faculties from Baxter International
• Explore a back to back Genentech session covering technical considerations for microbial QC of raw materials used in biotechnology and the past, current and future state of Mycoplasma testing

• Rebecca Jordan, QC Microbiology Sr Specialist, Juno Therapeutics
• Elia Sanchez, QC Microbiology Sr. Manager, Genentech
• Kenneth Tai, QC Scientist, Genentech
• Hilary Chan, Principal QC Scientist, Takeda
• Maria Dunnells, Sr. Manufacturing Lead Investigator, Takeda
• Steven Wieczorek, Associate Director QC, Sanofi
• Jim Polarine, Senior Technical Service Manager, STERIS Corporation
• Steve Walton, Sr Sterility Assurance Lead, Baxter International

In addition to the agenda, there will also be a half-day post-conference workshop held on 1st May 2020. The workshop will be on ‘the use of recombinant chromogenic assays as alternate methods for the bacterial endotoxins test (BET),’ aiming to explore the global perspective on the use of synthetic reagents, including their regulatory status, and will be led by Veronika Wills, Manager, Technical Services, Associates of Cape Cod.

The full agenda and speaker line-up is available to view online at

Pharmaceutical Microbiology East Coast Conference
Conference: April 29th – 30th, 2020
Workshop: May 1st, 2020
Sheraton Boston Hotel, Boston, USA

For sponsorship enquiries contact Alia Malick on +44 (0)20 7827 6164 or

For media enquiries, contact Simi Sapal on +44 (0) 20 7827 6000 or

— ENDS –
About SMi Group:
Established since 1993, the SMi Group is a global event-production company that specializes in Business-to-Business Conferences, Workshops, Masterclasses and online Communities. We create and deliver events in the Defence, Security, Energy, Utilities, Finance and Pharmaceutical industries. We pride ourselves on having access to the world’s most forward-thinking opinion leaders and visionaries, allowing us to bring our communities together to Learn, Engage, Share and Network. More information can be found at

Simi Sapal
SMi Group
email us here

Source: EIN Presswire

Veterinary Endoscopes Market is estimated to Grow Significantly with 6.7% of CAGR by 2027

PUNE, MAHARASTRA, INDIA, November 28, 2019 / — According to a new market research study titled 'Veterinary Endoscopes Market to 2027 – Global Analysis and Forecasts by Product Type, Application, Procedure, End User and Geography'. The global veterinary endoscopes market is expected to reach US$ 478.84 Mn in 2027 from US$ 268.82 Mn in 2018. The market is estimated to grow with a CAGR of 6.7% from 2019-2027. The report highlights the trends prevalent in the global veterinary endoscopes market and the factors driving the market along with those that act as challenges to its growth.

Global the veterinary endoscopes market is segmented on the basis of product type, application, procedures and end user. The market based on product type segment is classified as capsule endoscopes, flexible endoscopes and rigid endoscopes. On the basis application the market is segmented as diagnostic and surgical. Based on the procedure the market is classified as bronchoscopy, cystoscopy, gastrointestinal, laparoscopy, otoscopy, and other procedure types. And on the basis of end user the market is divided into veterinary clinic, veterinary hospitals and other end users.

Get Sample PDF Copy at

The market for veterinary endoscopes is expected to grow significantly due to factors such increasing pet animal’s population, growing training programs for endoscopic diagnosis and rising incidences of zoonotic diseases over the forecasted years. Also, the growth opportunities in the developing nations are likely to have a positive impact on the growth of the market in the coming years

Global Veterinary Endoscopes Market – By Product Type

– Capsule Endoscopes
– Flexible Endoscopes
– Rigid Endoscopes

Global Veterinary Endoscopes Market – By Application

– Diagnostic
– Surgical

Global Veterinary Endoscopes Market – By Procedure

– Bronchoscopy
– Cystoscopy
– Gastrointestinal
– Laparoscopy
– Otoscopy
– Other Procedure Types

Global Veterinary Endoscopes Market – By End User

– Veterinary Clinic,
– Veterinary Hospitals
– Other End Users

Buy Complete Report at

Sameer Joshi
The Insight Partners
+91 9666111581
email us here

Source: EIN Presswire

IoT in Healthcare Market Expected to Grow at a CAGR of 21.2% During the Forecast Period to 2025

PUNE, MAHARASHTRA, INDIA, November 28, 2019 / — According to the new research report published by The Insight Partners, titled “IoT in Healthcare – Global Analysis and Forecast to 2025”, the global IoT in healthcare market is expected to reach US$ 135.9 Bn in 2025, registering a CAGR of 21.2% during the forecast period 2017-2025.

In 2025, North America is expected to account for more than one-third of total IoT in healthcare revenue market share. The growth is majorly driven by enhanced IoT infrastructure in the region with better connectivity, availability of skilled professionals and rising incidences of chronic diseases such as obesity, diabetes etc.

Get Sample PDF Of Report@

The IoT in Healthcare market is experiencing a high growth and adoption rate from past few years and is also expected to experience a significant growth and adoption rate in years to come. One of the major reason for high adoption of IoT in Healthcare is the need to decrease costs related to healthcare facilities worldwide. Developing economies with high growth in population and decreasing prices for internet services are providing opportunities for the players operating in the global IoT in Healthcare market. Few of the player that are operating successfully in global IoT in Healthcare market are Koninklijke Philips N.V., GE Healthcare, IBM Corp., Microsoft Corporation and others. Few of the factors that might act as a hindrance in the growth of the IoT in Healthcare market are high costs associated to smart devices and IoT infrastructure, and security and privacy concerns related to theft of highly confidential and sensitive health data of the patients.

Technology up gradation, government initiatives to deploy IoT solutions in healthcare industry, rising incidences of chronic diseases, and continuously increasing adoption of smart devices are some of the key driving factors for this market. Many healthcare institutions and providers are adopting IoT in healthcare solutions to deliver better care to their patients and optimize their clinical workflow. The global IoT in Healthcare market is broadly classified into solution (medical systems & devices and software solutions & tools), services (professional services & integration services) application (medication management, patient monitoring, fitness & wellness measurement, clinical workflow management and others) and end-user (patients & individuals, diagnostic & research and labs, hospitals & healthcare institutes and government authority); and geography.

Some Of Major Key Players In IoT in Healthcare Market:-

Koninklijke Philips N.V.,Medtronic Plc, Siemen Healthcare GmbH, Proteus Digital Health, Inc., IBM Watson Health, General Electric Healthcare, Microsoft Corporation, Qualcomm Life, Inc., STANLEY Healthcare, Verily Life Sciences LLC (Alphabet-Google)

Strategic Insights:

Market initiative was observed as the most adopted strategy in global IoT in Healthcare market. Few of the recent strategies by some of the players in IoT in Healthcare market landscape are listed below-

2016: The Office of the National Coordinator for IT (ONC) released Interoperability Standards Advisory (ISA) for the year 2017. This will enable patients’ to easily access their health data. This is an update to the ISA released in 2016.

2016: European Institute of Innovation and Technology for Health (EIT Health) funded a new research project in which Florida Atlantic University, Siemens Healthcare GmbH, Universitätsklinikum Erlangen along with other European partners will work together to develop a hybrid device for quicker diagnosis and treatment of strokes.

2016: IBM Watson Health partnered with Finnish Funding Agency for Innovation with an aim to enable Finland to utilize Watson cognitive computing to facilitate doctors enhance the health of Finland’s citizens, and support and develop the Finnish innovation and business ecosystem in the fields of health and well-being.

Wearable healthcare devices to boost the IoT in Healthcare market:-

IoT has a significant role to play in monitoring the health and safety of individual. Numerous pioneering wearable technologies have been developed in recent years that intent to revolutionize healthcare industry. Integration of IoT and wearable devices such as smart watch or health bands help to empower and educate patients to take control of their health and in turn boost the growth of IoT in Healthcare market. Some wearable devices also send data related to functioning of organs and disease markers to the physicians and helping in monitoring and diagnosing disease. Other wearable or portable health monitoring devices such as blood glucose level monitor helps diabetes patients in monitoring blood glucose levels, track food intake and deliver insulin and transmit the related data to their physicians. The number of health benefits of wearable devices and integration of IoT is further expected to result in reducing the overall treatment time and ease doctor patient interactions. Hence, wearable healthcare devices are expected to fuel the growth of IoT in Healthcare market in the coming years.

Adoption of connected medical devices fuelling the growth of IoT in Healthcare market:-

The adoption of IoT in Healthcare solution is witnessing a high growth and increasing need for integration and connectivity tools in escalating operations of healthcare organizations are the factors driving the growth of IoT in Healthcare market. The constantly decreasing costs of sensors embedded in these devices have resulted in falling prices of connected devices and hence, the adoption of connected medical devices have further increased. These devices connected to the internet and enable the healthcare professionals to get real-time information regarding patients’ health and helps in efficient monitoring. Furthermore, these devices send alerts to the nearby hospital in case of any emergency. Also, connected medical devices save lengthy communicating process between patients and healthcare providers. The valuable data recorded in the cloud through these devices helps in better diagnosis and analysis thereby, improving patients’ care. This trend is expected to further increase the growth of IoT in Healthcare market.

Buy This Research Report@

Sameer Joshi
The Insight Partners
+1 646-491-9876
email us here

Source: EIN Presswire

Sanger Sequencing Service Market is Growing with $1,360.47 Million by 2027 and 12.2% of CAGR

Sanger sequencing is mainly recognized for DNA sequencing and supports applications in RNA sequencing and epigenetic analysis.

PUNE, MAHARASTRA, INDIA, November 27, 2019 / — Sanger sequencing is the superior method for sequencing, and it is a process of incorporation of chain-terminating dideoxynucleotides by DNA polymerase during in vitro DNA replication. Sanger sequencing is known to provide high accuracy, long-read capabilities, and adaptability to support a diverse range of applications in many research areas.

Many of the evolving biotechnology and genetics start-ups are using DNA sequencing technologies for various applications. These new emerging companies are offering sequencing services that analyze human and animal genomes. For instance, located in Baltimore, United States, Personal Genome Diagnostics Inc. was founded in 2010 and is involved in genome analysis of human tumors. The company develops a patient-specific analysis of cancer by using sequencing tools and technologies.

Get Sample PDF Copy at

According to a new market research study titled ‘Sanger Sequencing Service Market to 2027 – Global Analysis and Forecasts by Application, End User, and Geography.’ The global Sanger sequencing service market is expected to reach US$ 1,360.47 Mn in 2027 from US$ 489.43 Mn in 2018. The market is forecasted to grow with a CAGR of 12.2% during 2019-2027. The report highlights the trends prevalent in the global Sanger sequencing service market and the factors driving the market along with those that act as deterrents to its growth.

Global Sanger Sequencing Service Market – By Application

– Diagnostics
– Biomarkers and Cancer
– Reproductive Health
– Personalized Medicine
– Forensics
– Other Applications

Global Sanger Sequencing Service Market – By End User

– Academic and Government Research Institutes
– Biotechnology Companies and Pharmaceutical Companies
– Hospitals and Clinics
– Other End Users

The global Sanger sequencing service market, based on application, was segmented as, diagnostics, biomarkers and cancer, reproductive health, personalized medicine, forensics, and other applications. In 2018 biomarkers and cancer held the largest share of the market, by application, due to the rising incidence of cancer, increasing the use of cancer biomarkers in drug discovery and diagnostics, and increasing research on cancer biomarkers.

The market for Sanger sequencing service is expected to grow owing to factors such as increasing providers for Sanger sequencing services and growing applications of Sanger sequencing. Also, an increase in the number of startup companies for genome analysis is expected to have a positive impact on the growth of the market in the coming years.

Buy Complete Report at

Sameer Joshi
The Insight Partners
+1 646-491-9876
email us here

Source: EIN Presswire

Dr. Mark Fleckner Explains The Difference Between An Optometrist And Ophthalmologist

Dr. Mark R. Fleckner, MD

GARDEN CITY, NEW YORK, UNITED STATES, November 27, 2019 / — Dr. Mark Fleckner is a board-certified New York ophthalmologist. Mark R. Fleckner MD’s areas of expertise include treating diseases affecting the retina.

Dr. Mark Fleckner’s practice strives to ensure patients are comfortable and well-informed about their treatments. This includes advising patients about which eye expert to see for which eye problem.

Accurately choosing an eye care provider is a significant health care decision. One, we often undervalue.

Some people do not know the difference between an optometrist and an ophthalmologist. Dr. Mark Fleckner wants to clear up the confusion to help people find the right treatment for their eyes.

You need to put your trust in your eye care professional. It is how you can safeguard your valuable sense of sight and maintain a lifetime of good vision.

But first, you need to know what type of eye doctor to visit when eye issues occur.

“There is a distinct difference between the two eye care professionals. Optometrists offer medical treatment for common eye problems. However, ophthalmologists treat certain eye disorders. Particularly if it involves specialty care or surgery,” says Mark R. Fleckner, MD.

Common eye problems optometrists handle include dry eyes and eye infections.

Ophthalmologists like Dr. Mark Fleckner, help patients with certain eye diseases. For example, diabetic retinopathy and macular degeneration.

Furthermore, each of these eye experts receives a different education for their specialties.

– An optometrist is an eye doctor who has earned the Doctor of Optometry (OD) degree.

– Specialties: An optometrist examines eyes for both vision and health problems. He or she corrects refractive errors by prescribing eyeglasses and contact lenses.

– An ophthalmologist is a medical doctor and a specialist in ophthalmology. Ophthalmologists generally complete four years of college and four years of medical school.

Ophthalmologists need to complete a one-year internship. All have to finish at least three years of hospital-based residency in ophthalmology.

– Specialties: An ophthalmologist performs eye exams, diagnoses, and treats certain eye diseases. He or she can prescribe medications and perform eye surgery.

Another way to look at it is to extend the analogy with dentistry. The education of an optometrist is like a general dentist. Whereas, the education and training of an ophthalmologist like an oral surgeon.

Mark R. Fleckner MD emphasizes the importance of regular eye exams. He does not want people to make their own diagnosis. He stresses how essential it is to visit an eye care professional.

It is vital to know the difference between an optometrist and an ophthalmologist. This awareness will be helpful to many people experiencing eye issues.

It is from this new understanding that people can start making better eye care decisions.

To learn more about Mark R. Fleckner MD, visit

Caroline Hunter
Web Presence, LLC
+1 7862338220
email us here

Source: EIN Presswire

At 8.1% of CAGR, Pre-Clinical CROs Market is Growing with $8,412.9 Million by 2027

The global pre-clinical CROs market expected to be US$ 4,282.42 Mn in 2018 and is predicted to grow at a CAGR of 8.1% during the forecast period 2019 – 2027

PUNE, MAHARASTRA, INDIA, November 27, 2019 / — A rise in outsourcing activities by pharmaceutical companies has been witnessed during recent years. This trend has been seen as a plan to remain competitive and flexible in a market of exponential growth, sophisticated technologies, and an unstable economic environment. Companies generally outsource R&D tasks which include a broad range of activities such as, fundamental research to late-stage development: hit exploration and lead optimization, target validation, genetic engineering, assay development, safety and efficacy tests in animal models, and clinical trials which involve humans.

The major factors driving the growth of outsourcing activities by companies are, cutting costs, need for innovations, increased speed and agility, and accessing specialized knowledge and technologies. A decreasing percentage of profits has become a primary concern for pharmaceutical companies over the past decade. As per an analysis by PhRMA, around $0.8 to $1.7 billion is estimated to be invested by the pharmaceutical industry in R&D to bring a new drug to market. Hence, with an increase in the R&D expenditure, the need for pre-clinical services is expected.

Get Sample PDF Copy at

Clinical trials are a vital step in discovering whether the medical strategy, treatment, or device is safe and effective for human use. It is one of the engines that drive innovation in the biopharmaceutical sector. Clinical studies help in understanding as well as determining the most suitable medical approaches for a particular therapeutic area. These trials are conducted primarily to collect data regarding the safety and efficacy of a new drug and device development. Before the approval of molecules and medical devices by the regulatory authorities, a series of clinical studies are carried out. Increasing prevalence of chronic diseases is increasing the demand for the development of new drugs or medical devices for the treatment.

According to a report published by Seeker Health, at any given point, there are approximately 6000 clinical trials for which patients enroll across the globe. This is in turn expected to increase the demand of the clinical trial activities for various therapeutic areas, hence driving the growth of the pre-clinical CROs market.


By Service

– Bio-Analysis and DMPK Studies
– Toxicology
– Other Services

By End User

– Biopharmaceutical Companies
– Government and Academic Institutes
– Medical Device Companies

Increasing R&D expenditures and high cost of drug development process in the developed countries have been boosting the market over the years. However, stringent regulations for conduction of clinical trials and variations in the GMP guidelines across countries around the globe are likely to have a negative impact on the growth of the market in the coming years.

The major players operating in the pre-clinical CROs market include, Covance, Inc., Charles River, Eurofins Scientific, PRA Health Sciences, WuXi AppTec, Medpace, Inc., Pharmaceutical Product Development, LLC, Parexel International Corporation, ICON Plc, and MD Biosciences among the others. The market has witnessed various organic as well as inorganic developments during recent years in the pre-clinical CROs market. For instance, in September 2019, Pharmaceutical Product Development, LLC (PPD) expanded its bio-analytical laboratory in Richmond, Virginia, enhancing immunochemistry, biomarker and chromatography services for biopharmaceutical clients.

Buy Complete Report at

Sameer Joshi
The Insight Partners
+1 646-491-9876
email us here

Source: EIN Presswire

Allele Expands Portfolio with New Stem Cell Patent Issued in Under One Year

New patent supports Allele to produce clinical grade iPSC lines in its own cGMP cleanroom facility in California

The USPTO has awarded yet another patent to Allele Biotech on iPSC generation using synthetic messenger RNA (mRNA), as Allele enters multiple partnership deals.

SAN DIEGO, CA, USA, November 27, 2019 / — By Daniel Catron

Allele’s latest patent extends coverage of the generation of feeder-free induced pluripotent stem cells using synthetic messenger RNA (mRNA).

The United States Patent and Trademark Office has awarded invention number 10,435,711 to Allele Biotechnology and Pharmaceutical, Inc. This patent describes additional methods and conditions of generating induced pluripotent stem cells (iPSC) based on Allele’s core technologies in a highly controlled and reproducible process. It is the third in the patent family of novel approaches to generating iPSCs for the company.

This patent marks the fastest to issue in Allele’s growing portfolio, having been granted in less than a year after filing, joining the first two Allele iPSC patents granted in late 2018. Other patents in the portfolio address the composition of mRNA used to reprogram cells to become stem cells and processes of doing so in an efficient and clinically relevant manner. All of these patents have also being granted or in the process of being granted around the world.

This newly issued patent arrives with excellent timing as Allele realizes its goal of overcoming bottlenecks in the regenerative medicine and cell therapy fields. The industry, now moving to reproducibly provide pancreatic beta cells for diabetes, neural progenitor cells for dementia, or unlimited supply of CAR-NK or CAR-T for treating cancers, etc., is growing rapidly and needs appropriate source of upstream pluripotent stem cells such as cGMP iPSCs that are amenable to regulatory review. Dr. Jiwu Wang, Allele’s Founder and CEO, is the patent’s inventor and is “pleased to be a source of iPSC lines for all clinical applications.”

Allele Biotechnology and Pharmaceuticals is a biotherapeutics company founded in 1999. In 2015, the company completed an 18,000 square foot state-of-the-art facility in San Diego for the production of cGMP-grade human iPSC lines. The facility also supports the cGMP production of tissue-specific cells differentiated from these iPSCs, including pancreatic beta cells, neural progenitor cells, and cardiomyocytes. Allele has already generated dozens of clinical-grade iPSC lines and is actively partnering with companies to produce custom lines and differentiated cells.

Dan Catron
Allele Biotechnology and Pharmaceuticals, Inc.
email us here
+1 858-587-6645
Visit us on social media:

Source: EIN Presswire

Global Psoriasis Drugs Market 2019 Key Players, Trends, Sales, Supply, Demand, Analysis and Forecast 2025 adds “Psoriasis Drugs Global Market Report 2022” reports to its database.

PUNE, MAHARASTRA, INDIA, November 27, 2019 / — Psoriasis Drugs Market:

Executive Summary

The psoriasis drugs market consists of sales of psoriasis drugs. Psoriasis is a persistent skin disorder which causes distress and pain through patches of abnormal skin. Psoriasis can be caused due to injuries to skin, medications, genetics, infection, diet, weather, etc. The drugs vary depending on the severity of the infection and provide relief from infections. Examples of drugs in the psoriasis market include Clobetasol (Temovate), triamcinolone (Aristocort), fluocinolone (Synalar), and betamethasone (Diprolene).

The global psoriasis market was valued at about $30.13 billion in 2018 and is expected to grow to $46.57 billion at a CAGR of 11.5% through 2022.

North America was the largest region in the psoriasis drugs market in 2018. This region is expected to remain the largest during the next five years. The psoriasis drugs market in Asia Pacific is forecasted to register the highest CAGR during 2018-2023.

Request Free Sample Report @

The rise in the prevalence of psoriasis patients is driving the Psoriasis market. Psoriasis is caused due to immune system, genetics and environment. The rise in psoriasis patients in the past few years can be mainly attributed to climate change, stress and unhealthy lifestyle. According to the World Health Organization (WHO), psoriasis had affected at least 100 million individuals worldwide in 2016.

The high cost of psoriasis therapy is a restraint for the psoriasis market. According to a study conducted by JAMA Dermatology in 2019, the typical psoriasis treatments with biologics are very costly, ranging between $10,000 and $25,000 per year. The high cost is because patent protections are preventing many alternative drugs.

Combination therapy is an emerging trend in the psoriasis market. Combination therapy is an f treatment that combines two different psoriasis treatments at the same time. When two drugs with different mechanisms of action are combined (combination therapy), the effect is greater than that obtained by monotherapy (treatment with a single drug). Studies suggest that combination therapy eases psoriasis symptoms more effectively than a single therapy and has lesser side effects. An example of combination therapy for the treatment of active psoriatic arthritis (PsA) is taltz (ixekizumab) with methotrexate developed by Eli Lilly and Company.

The process of approval of psoriasis drugs is becoming easier globally. This is evident from the increasing approvals of drugs for psoriasis in the recent years. Some of the examples include the first regulatory approval of SKYRIZI™ (risankizumab) for the treatment of plaque psoriasis in Japan in 2019, and the approval of a new treatment for plaque psoriasis in Europe in 2018. Hence, the increasing ease of drug approvals is expected to drive the psoriasis drugs market in the coming years.

Major players in the market are AbbVie Inc., Pfizer Inc., Novartis, Eli Lilly and Company and Celgene Corporation.


For further information on this report, visit –

email us here

Source: EIN Presswire